CIN: L24100HP2002PLC009299; Email Id: investorgrievancewmcl@gmail.com Registered Office: Suketi Road, Kala Amb, Sirmaur, Himachal Pradesh-173030

Date: 14.11.2024

To, To, Listing Department, Department of Corporate Services, Metropolitan Stock Exchange of India Limited **BSE LIMITED** (MSEI) P. I. Towers, Dalal Street, Vibgyor Towers, 4th Floor, Mumbai, Maharashtra-400001. Plot Number C 62, G - Block, Opposite Trident Hotel, Bandra Kurla Complex, Bandra (E), Mumbai, Maharashtra-400098. ISIN: INE730E01016 SYMBOL: PRISMMEDI Scrip Code: 512217

<u>Subject:</u> Outcome of the Board Meeting - Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to inform you that the Board of Directors at their meeting held today (i.e. 14th November, 2024) which commenced at 02:30 P.M. and concluded at 04:00 P.M. have inter alia approved the following:

- ➤ The Board considered and approved the Unaudited Standalone Financial Results of the company for the quarter and half year ended 30th September, 2024 along with the Limited Review Report duly signed by the Auditors of the company.
- > To accept the resignation of Mr. Vishwambhar Dayal Gupta (DIN: 00152580) as a Director of the company.

You are requested to kindly take the same on record and oblige.

Thanking You.

Yours Truly,

FOR PRISM MEDICO AND PHARMACY LIMITED

DAVENDER SINGH

DIRECTOR

DIN: 09447213



Harjeet Parvesh & Company

CHARTERED ACCOUNTANTS

(A PEER REVIEWED FIRM)

Limited Review Report on Standalone Financial Results

ToBoard of Directors of M/s Prism Medico & Pharmacy Limited

We have reviewed the Standalone Un-Audited Financial Result of M/s. Prism Medico And Pharmacy Ltd having its Regd. Office at Suketi Road, Kala Amb, Sirmaur, Himachal Pradesh - 173030 for the Quarter ended 30th September 2024 ("the Statement") attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015(as amended), including relevant circulars issued by the Securities and Exchange Board of India ('SEBI') from time to time.

This statement is the responsibility of company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Engagement to "Review of Interim Financial Information performed by the independent auditor of the entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material mis-statement. A review is limited primarily to inquiries of company personal and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of StandaloneUn-audited Financial Result prepared in accordance with applicable Accounting Standards i.e Indian Accounting Standards ('Ind AS') prescribed under section 133 of Companies Act, 2013, read with relevant rules issued there under and others recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulations 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Harjeet Parvesh & Co.

Chartered Accountants

CA Konica Madan M.No 547759

Date:14.11.2024

UDIN: 24547759BKFMQM7498

CIN: L24100HP2002PLC009299; EMAIL ID: INVESTORGRIEVANCEWMCL@GMAIL.COM REGISTERED OFFICE: SUKETI ROAD, KALA AMB, SIRMAUR, HIMACHAL PRADESH-173030

STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2024 (In Lakhs)

	PARTICULARS	Quarter Ended			Year to date	Year Ended (Audited)	Year Ended (Audited)
		30.09,2024	30.06.2024	30.09.2023	30.09.2024	31.03.2024	31.03.2023
I Ir	1come		· ·				
	Revenue from operations	28.78	6.27	3.27	35.05	292.52	127.06
L	Other income		0.21	1.06	0.21	12.22	0.17
T	otal income from operations	28.78	6.48	4.33	35.26	304.74	127.23
n E	xpenses						
	Cost of material consumed	23.68	4.80	5.07	28.48	256.08	114.07
	Change in inventories	-	-	-	-	- 1	*
	Employee benefit expenses	1.03	1.00	0.77	2.03	3.40	4.66
	Finance costs	-	0.04	-	0.04	0.71	0.03
	Depreciation and amortization expenses	0.13	0.13	0.13	0.26	0,53	0.66
	Other expenses	2.94	9.45	3.79	12.39	46.81	18.03
T	otal expenses	27.78	15.42	9.76	43.20	307.53	137.45
ш Р	rofit/(Loss) before exceptional items and tax	1.00	(8,94)	(5.43)	(7.94)	(2.79)	(10,22)
IV E	exceptional items	-	-			-	_
V P	rofit/(Loss) before tax	1.00	(8.94)	(5.43)	(7.94)	(2.79)	(10.22)
VI T	ax expenses						
	a) Current tax	-	-	-		-	
	b) Deferred tax	(0.06)	(0.06)	-	(0.12)	0.66	2.58
	b) Mat Credit		-			-	· · · · · · · · · · · · · · · · · · ·
	Net Profit/(Loss) for the period/year	0.94	(9.00)	(5.43)	(8.06)	(2.13)	(7.64)
VIII C	Other comprehensive income (net of tax)						
	Items that will not be reclassified to profit or loss:						
	obligations	-	-		-	0.12	_
	ii) Prior period income adjustment (Net of tax)	<u> </u>		-		0.12	
	Total other comprehensive income	-	-	- (7.10)	- (0.00)	0.12	(7.64)
	Total comprehensive income for the period/year VII+VIII)	0.94	(9.00)	(5.43)	(8.06)	(2.01)	(7.04)
I	Paid-up equity share capital (face value of the share	606,34	606.34	606.34	606.34	606.34	606.34
	hall be indicated)						
XI (Other equity (excluding revaluation reserve)	899.75	898.81	895,48	899.75	907.81	909.81
	EPS in Rs. (Face Value of Rs.10/- each)*					LONDON COST	
	- Basic	0,0002	(0.0015)	(0.0009)	(0.0013)		(0,0013)
	- Diluted	0.0002	(0.0015	(0.0009)	(0.0013)	(0.0004)	(0.0013)

- 1. The above results are as per Regulation 33 of the SEBI (LODR) Regulations, 2015 as amended and have been taken on record by Board of Directors at its meeting held on 14.11.2024 after being reviewed by the Audit Committee.
- 2. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- 3. The company is having single segment in accordance with IND AS 108 "Operating Segments" and therefore segment reporting is not applicable to the company.

FOR AND ON BEHALF OF THE BOARD PRISM MEDICO AND PHARMACY LIMITED

DAVENDER SINGH DIRECTOR DIN: 09447213

Place: KALA AMB, HIMACHAL PRADESH.

Date: 14TH NOVEMBER, 2024.

Prism Medico and Pharmacy Limited Statement of Assets and Liabilities For the half year ended on 30th September, 2024

	(Rs. In Lakhs)	(Rs. In Lakhs)
PARTICULARS	30TH SEPTEMBER, 2024	31ST MARCH, 2024
I. ASSETS		0.00000
(1) Non - Current Assets		
(a) Property, Plant and Equipment	3.10	3.36
b) Financial Assets	-	~
(1) Non-Current Investments	-	-
b) Deffered Tax Asset	21.91	22.03
	-	
(2) Current Assets	-	-
(a) Inventories	677.06	677.06
b) Financial Assets	-	-
(1) Cash and Cash Equivalent	7.98	8.36
(2) Short Term Loans and advances	351,24	351.24
(3) Trade Receivables	381.47	368.96
(c) Other Current Asset	73.52	93.29
	1,516.28	1,524.31
	4	
II. EQUITY AND LIABILITIES		
(1) Equity		
(a) Equity Share Capital	606.34	606.34
(b Other Equity	899.75	907.81
	· ·	-
(2) Current Liabilities	•	-
a) Financial Liabilties		-
(1) Trade Payables	4.68	3.08
(b) Other Current Liabilities	5.51	7.08
9	1,516.28	1,524.31

FOR AND ON BEHALF OF THE BOARD
PRISM MEDICO AND PHARMACY LIMITED

DIRECTOR DIN: 09447213

DAVENDER SINGH

Place: KALA AMB, HIMACHAL PRADESH.

Date: 14TH NOVEMBER, 2024.

Cash Flow Statement for the half year ended 30th September, 2024

		(Rs. In Lakhs)	(Rs. In Lakhs)
	Particulars	Year ended 30th September, 2024	
		Amount	Amount
A.	Cash Flow from Operating Activities:		
	Profit before tax for the year	(7.94)	(2.80)
	Adjustments for :	-	-
	Depreciation & Amortization	0.26	0.53
	Change in reserves	-	-
	Interest and Finance Charges	0.04	0.71
	Operating Profit Before Prior Period Items and Working Capital Change	(7.64)	(1.56)
	Operating Profit Before Working Capital Changes	(7.64)	(1.56)
	Adjustments for:	-	-
	Decrease/(Increase) in Receivables	(12.50)	107.15
	Inventories	=	-
	Other Current Assets	19.77	(93.20)
	Other Current Liabilties	(1.57)	(16.10)
	Increase/ (Decrease) in Trade Payables	1.60	3.08
		-	-
	Cash Generated from Gperations	(0.34)	(0.63)
	Income Tax Paid		0.13
	Net Cash from Operating Activities	(0.34)	(0.50)
В.	Cash Flow from Investing Activities:	-	-
ъ.	Investments sold		_
	Change in Loans and Advances	l -	_
	Change in Board and Tavaries	-	_
	Net Cash (used)/Genretated in Investing Activities	-	-
		-	-
C.	Cash Flow from Financing Activities:	(2.01)	(0.54)
	Interest and Other Finance Costs paid	(0.04)	(0.71)
	Net Cash (Used)/Generated in Financing Activities	(0.04)	(0.71)
		-	-
	Net Increase in Cash and Cash Equivalents (A)+(B)+(C)	(0.38)	(1.21)
	Opening Cash and Cash Equivalents	8.36	9.57
	Closing Cash and Cash Equivalents	7.98	8.36

FOR AND ON BEHALF OF THE BOARD PRISM MEDICO AND PHARMACY LIMITED

DAVENDER SINGH

DIRECTOR DIN: 09447213

Place: KALA AMB, HIMACHAL PRADESH.

Date: 14TH NOVEMBER, 2024.

Dote: 14-11-2024

To

The Board of Directors

Prism Medico And Pharmacy Limited

Sub: Resignation from Directorship

Sir,

I, Vishwambhar Dayal Gupta R/o House no 7, Sector 4, HUDA, Naraingarh, Haryana, due to personal and unavoidable circumstances, I do hereby tender my resignation from the Directorship of the Company with immediate effect. Kindly accept this letter as my resignation with immediate effect from the post of Director of the Company and relieve me of my duties.

Kindly acknowledge the receipt of this resignation letter and arrange to submit the necessary forms with the office of the Registrar of Companies, to that effect.

Thanking You,

Vishwambhar Dayal Gupta

DIN:00152580

CIN: L24100HP2002PLC009299; Email Id: investorgrievancewmcl@gmail.com Registered Office: Suketi Road, Kala Amb, Sirmaur, Himachal Pradesh-173030

TEXT OF RESOLUTION PASSED AT A DULY CONVENED MEETING OF BOARD OF DIRECTORS OF THE COMPANY HELD DURING THE FINANCIAL YEAR 2024-2025 ON THURSDAY, THE 14TH DAY OF NOVEMBER, 2024 AT 02:30 P.M. AT THE REGISTERED OFFICE OF THE COMPANY SITUATED AT SUKETI ROAD, KALA AMB, SIRMAUR, HIMACHAL PRADESH-173030.

2. TO APPROVE THE UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2024.

The Board discussed and then passed the following resolution:

"RESOLVED THAT pursuant to the applicable provisions of the Companies Act, 2013 and Rules made thereunder (including any statutory modification or re-enactment(s) thereof for the time being in force) and Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 the unaudited standalone financial results of the company for the quarter and half year ended 30th September, 2024 as reviewed by the Audit Committee and tabled before the Board be and hereby approved."

"RESOLVED FURTHER THAT Mr. Davender Singh, Director of the company be and is hereby authorized to sign the said statement of accounts and to do all such acts, deeds, and things as may be necessary to give effect to the above said resolution."

CERTIFIED TO BE TRUE COPY
FOR PRISM MEDICO AND PHARMACY LIMITED

DAVENDER SINGH

DIRECTOR (DIN: 09447213)

2) oursely

VILLAGE DHALOUR, P.O. SHERPUR,

SALKHANI, SARAWAN, YAMUNANAGAR,

HARYANA-133206.